- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06938412
Intervento di attività di esercizio con impegno a base di sensori in pazienti con fibrillazione atriale (EASE-AF)
Intervento di attività di esercizio con impegno a base di sensori in pazienti con fibrillazione atriale (facilità-AF)
Atrial fibrillation (AF) affects 1 in 4 individuals during their lifetime and continues to increase in frequency and impact. Exercise intervention has established benefits to improve AF symptoms and burden in clinical studies. However, lack of access to exercise programs has limited therapeutic adoption. The growth of technology-driven health care and diagnostics, recognized as an emerging priority by the American Heart Association, offers an opportunity for a pragmatic and patient-centered approach to meet this need. EASE-AF is a prospective, interventional study with a sequential run-in control to evaluate if a digital health-driven, patient-centered exercise intervention improves AF symptoms and burden. The research team will enroll 120 patients with symptomatic, non-permanent AF. The main impact of this study will be the establishment of evidence for a novel, pragmatic paradigm for a patient-centered, digital technology-driven personalized exercise intervention for patients with AF.
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Jaclyn Printz
- Numero di telefono: 917-991-674
- Email: EASE-AF@mountsinai.org
Backup dei contatti dello studio
- Nome: Jaclyn Printz
- Numero di telefono: 212-824-7077
- Email: Jaclyn.Printz@mountsinai.org
Luoghi di studio
-
-
New York
-
New York, New York, Stati Uniti, 10029
- Reclutamento
- Icahn School of Medicine at Mount Sinai
-
Investigatore principale:
- Janice Y Chyou, MD
-
Contatto:
- Jaclyn Printz
- Email: EASE-AF@mountsinai.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- ≥40years of age
- non-permanent AF
- Electrocardiographic (or equivalent) documentation of AF within 36 months (would need to have evidence of AF after initial post-ablation blanking period if the patient had prior AF ablation)
- AF Severity Scale (AFSS) symptom score 6-26
- Self-report weekly moderate-vigorous physical activity (MVPA) < 150 minutes
Exclusion Criteria:
- Unable to give consent
- ≤90 days from AF ablation, coronary revascularization, heart failure hospitalization
- Left ventricular ejection fraction (LVEF) <40%, moderate to severe stenotic valvular heart disease or severe regurgitant valvular disease or history of mechanical valve replacement, presence of implanted pacemaker or defibrillator system
- Labile INR or unable to take anticoagulant despite indication
- Life expectancy < 1 year
- Hemodialysis; severe pulmonary or liver disease
- Musculoskeletal, balance/gait issues, severe peripheral vascular disease, or neuropathy or other neurologic conditions limiting exercise
- Upon initial screening, if the participant's baseline FitBit-measured MVPA ≥180 minutes/week (despite self-report range of <150 minutes), the participant will be further excluded.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Patients With Atrial Fibrillation
Patients with symptomatic, non-permanent AF. |
The intervention is a digital technology-driven, patient-centric approach to physical activity and exercise intervention with tailored digital engagement and progressive physical activity goals (the intervention). The intervention will be conducted using FitBit wearable device. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Atrial Fibrillation Severity Scale (AFSS), Symptom Severity Domain
Lasso di tempo: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
The Symptom Severity domain (Part C) of the validated Atrial Fibrillation Severity Scale (AFSS) questions patients regarding the severity of 7 AF-related symptoms (on scale of 0-5 per question, 5 denoting a great deal of symptom and 0 with no symptom) over the preceding 4-week period. Total scores range 0-35 on the Symptom Severity Domain of the Atrial Fibrillation Severity Scale (AFSS), higher score denotes more severe AF-related symptoms. |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Atrial Fibrillation Severity Scale (AFSS)
Lasso di tempo: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
The full Atrial Fibrillation Severity Scale (AFSS) is composed of 19-items, investigating four domains: global well-being, symptom burden, health care utilization, symptom severity. Global well-being: 1-10; 10 denotes best possible quality of life. Symptom burden: Composite of AF burden as AF duration + AF frequency + AF severity; ranging 0-30, higher denotes more symptom burden. Health care utilization: ER visits (0-7, higher number denotes more utilization), Hospitalizations (0-7, higher number denotes more utilization), Specialist visits (0-7, higher number denotes more utilization); Symptom Severity: 0-35, higher score denotes more severe AF-related symptoms |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
AF Arrhythmia Burden: Percentage of time in AF
Lasso di tempo: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Global AF arrhythmia burden will be measured as percentage of time in AF measured during an 8-14-day monitoring period at the end of each time point as quantified by either clinically validated patch-based monitoring system or loop recorder. |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
AF Arrhythmia Burden: Duration of longest AF Arrhythmia Episode
Lasso di tempo: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Duration of the longest AF episode during the monitoring period will be quantified by either clinically validated patch-based monitoring system or loop recorder. |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
Weekly Step Counts
Lasso di tempo: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Weekly step counts measured by FitBit wearable device provided by the study |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
|
Weekly Exercise Minutes
Lasso di tempo: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Weekly exercise minutes measured by FitBit wearable device provided by the study |
Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Janice Y Chyou, MD, Icahn School of Medicine at Mount Sinai
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- STUDY-24-00464
- 24SCEFIA1249819 (Altro numero di sovvenzione/finanziamento: American Heart Association)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Not planning to share individual participant data. Aggregate data will be shared instead.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .